STOCK TITAN

Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in the virtual Goldman Sachs Healthcare Corporate Day.

Genetron’s management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan Xu, Chief Financial Officer, will attend investor meetings on Friday, June 24, 2022.

Interested parties may request more information by contacting their sales representative at Goldman Sachs.

About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit https://ir.genetronhealth.com/.

Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
Email: ir@genetronhealth.com


Genetron Holdings Ltd

NASDAQ:GTH

GTH Rankings

GTH Latest News

GTH Stock Data

Medical Laboratories
Health Care and Social Assistance
Link
Health Services, Medical/Nursing Services, Health Care and Social Assistance, Medical Laboratories

About GTH

genetron holdings limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. the company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as hccscreen, a proprietary assay for the early screening of liver cancer. it also provides in-vitro diagnostics products, including 8-gene lung cancer assay, an ivd assay product based on semiconductor sequencing to detect lung cancer; genetron 3d biochip reading instrument; idh1/tert gene assays for glioma; genetron s5, a semiconductor sequencer used in the field of gene detection; and genetron s2000 that enables gene panel sequencing. in addition, the company develops ctdna lung cancer assay for mutations in the epidermal growth factor receptor gene. it also offers development services in the areas of genomics research and clinical development in collabor